FLC Capital Advisors Has $1.40 Million Stake in Pfizer Inc. $PFE

FLC Capital Advisors lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 1.4% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 57,692 shares of the biopharmaceutical company’s stock after selling 798 shares during the period. FLC Capital Advisors’ holdings in Pfizer were worth $1,398,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer in the first quarter valued at about $27,000. North Capital Inc. bought a new stake in Pfizer in the 1st quarter valued at about $28,000. Bayforest Capital Ltd acquired a new position in shares of Pfizer during the 1st quarter worth approximately $28,000. Harbor Asset Planning Inc. acquired a new position in shares of Pfizer during the 2nd quarter worth approximately $29,000. Finally, Horizon Financial Services LLC bought a new position in shares of Pfizer during the first quarter worth approximately $35,000. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on PFE. UBS Group reiterated a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Bank of America increased their target price on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Citigroup boosted their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Finally, Morgan Stanley cut their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday, October 10th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $28.13.

Pfizer Price Performance

Pfizer stock opened at $24.52 on Monday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $29.36. The stock has a market capitalization of $139.38 billion, a P/E ratio of 13.04, a price-to-earnings-growth ratio of 0.81 and a beta of 0.55. The stock has a fifty day moving average of $24.89 and a 200-day moving average of $24.11.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 7.0%. Pfizer’s dividend payout ratio is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.